Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder

This study has been completed.
Information provided by:
Shaare Zedek Medical Center Identifier:
First received: August 15, 2006
Last updated: August 16, 2011
Last verified: July 2006
Using a virtual reality program in screening and treatment of ADHD.

Condition Intervention Phase
Drug: methylphenidate
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder

Resource links provided by NLM:

Further study details as provided by Shaare Zedek Medical Center:

Primary Outcome Measures:
  • Virtual Reality program test results

Estimated Enrollment: 40
Study Start Date: August 2006
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Virtual Reality is a novel program designed to imitate a real classroom environment including various distractions. It includes a head monitor to track eye movements Children aged 10-20 years with ADHD will use the program with and without methylphenidate(1 mg/kg). Their results will be compared to a control group.

Parental consent will be obtained.


Ages Eligible for Study:   10 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Clinical diagnosis of ADHD-DSM4 criteria AGE 10-20 YEARS normal neurological examination IQ>80

Exclusion Criteria:


  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00364702

Shaari Zedek Pediatric Neurology Unit
Jerusalem, Israel, 91031
Sponsors and Collaborators
Shaare Zedek Medical Center
Study Chair: V. Gross, Prof/ md Shaari Zedek Pediatric Neurology Unit
  More Information

No publications provided Identifier: NCT00364702     History of Changes
Other Study ID Numbers: 45/04
Study First Received: August 15, 2006
Last Updated: August 16, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Shaare Zedek Medical Center:
Virtual Reality

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders
Mental Disorders Diagnosed in Childhood
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2015